CPDU Revenue first quarter 2014 Y/Y Growth Comment
China Pediatric Pharmaceuticals, Inc. achieved in the first quarter 2014, above Company average Revenue rise of 79.68% year on year, to $ 1.58 millions.
Looking into first quarter 2014 results within Healthcare Facilities industry 3 other companies have achieved higher Revenue growth. While China Pediatric Pharmaceuticals, Inc.' s Revenue jump of 79.68% ranks overall at the positon no. 326 in the first quarter 2014.
CPDU Revenue ( Y/Y Growth %)
2014
2013
2012
2011
4th Quarter
December
-
-7.44 %
-83.89 %
18.45 %
3rd Quarter
September
-
-59.69 %
-69.89 %
13.22 %
2nd Quarter
June
-
-84.74 %
-7.23 %
-
1st Quarter
March
79.68 %
-81.78 %
-28.55 %
-
FY
-
-73.66 %
-48.36 %
-
Financial Statements
China Pediatric Pharmaceuticals,'s first quarter 2014 Revenue
Revenue by Quarter for the Fiscal Years 2011, 2012, 2013, 2014
China Pediatric Pharmaceuticals,'s Q/Q Revenue Growth
Revenue Q/Q Growth Statistics
High
Average
Low
42.83 %
-4.05 %
-68.18 %
(Dec 31 2013)
CPDU's I. Quarter Q/Q Revenue Comment
China Pediatric Pharmaceuticals, Inc. achieved in the I. Quarter 2014 above company average sequential Revenue jump of 41.18%, to $ 1.58 millions, from $1.12 millions in the fourth quarter.
Within Healthcare Facilities industry 5 other companies have achieved higher Revenue quarter on quarter growth. While China Pediatric Pharmaceuticals,'s Revenue growth quarter on quarter, overall rank is 279.
China Pediatric Pharmaceuticals, Inc. achieved in the I. Quarter 2014 above company average sequential Revenue jump of 41.18%, to $ 1.58 millions, from $1.12 millions in the fourth quarter.
Within Healthcare Facilities industry 5 other companies have achieved higher Revenue quarter on quarter growth. While China Pediatric Pharmaceuticals,'s Revenue growth quarter on quarter, overall rank is 279.
China Pediatric Pharmaceuticals,'s 12 Months Revenue Growth Year on Year
Revenue TTM Growth
12 Months Ending (Mar 31 2014)
12 Months Ending (Dec 31 2013)
12 Months Ending (Sep 30 2013)
12 Months Ending (Jun 30 2013)
12 Months Ending (Mar 31 2013)
Cumulative Revenue 12 Months Ending
$ 4.42
$ 3.73
$ 3.82
$ 4.99
$ 10.22
Y / Y Revenue Growth (TTM)
-56.69 %
-73.7 %
-81.35 %
-80.05 %
-59.92 %
Year on Year Revenue Growth Overall
Ranking
# 3026
# 3028
# 0
# 0
# 0
Seqeuential Revenue Change (TTM)
18.75 %
-2.36 %
-23.53 %
-51.15 %
-27.89 %
Seq. Revenue Growth (TTM) Overall
Ranking
# 183
# 178
# 0
# 0
# 2529
Cumulative Revenue growth Comment
China Pediatric Pharmaceuticals, showed decline, but improvement compare to trailing twelve month Revenue decrease in Dec 31 2013. If the fiscal year would end in Mar 31 2014, China Pediatric Pharmaceuticals,'s annual Revenue drop would be -56.69% year on year to $4 millions.
In the Healthcare sector 322 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 3026, from total ranking in previous quarter at 3028.
China Pediatric Pharmaceuticals, showed decline, but improvement compare to trailing twelve month Revenue decrease in Dec 31 2013. If the fiscal year would end in Mar 31 2014, China Pediatric Pharmaceuticals,'s annual Revenue drop would be -56.69% year on year to $4 millions.
In the Healthcare sector 322 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 3026, from total ranking in previous quarter at 3028.
About China Pediatric Pharmaceuticals, Revenue Growth Rates (CPDU), Current and Historic Growth - CSIMarket Analysis
How we calculate this
This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years).
Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
139.09%